Xtl Biopharmaceuticals (XTLB) Cash & Equivalents (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Cash & Equivalents for 17 consecutive years, with $76000.0 the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 79.51% year-over-year to $76000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $76000.0 (down 79.51% YoY) and the FY2025 annual result came in at $76000.0, down 79.51% from the prior year.
• Cash & Equivalents slipped to $76000.0 in Q4 2025 per XTLB's latest filing, from $150000.0 in the prior quarter.
• Over the last five years, Cash & Equivalents for XTLB reached as high as $3.4 million in Q1 2021 and fell as low as $76000.0 in Q4 2025.
• A 5-year average of $1.7 million and a median of $1.7 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents declined 17.74% — and 2025, when it plunged 79.51%.
• Year by year, Cash & Equivalents stood at $3.0 million in 2021, then decreased by 29.47% to $2.1 million in 2022, then sank by 33.09% to $1.4 million in 2023, then sank by 73.52% to $371000.0 in 2024, then tumbled by 79.51% to $76000.0 in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $76000.0, $150000.0, and $371000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.